Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 24 Sep 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 20 Sep 2019 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 20 Sep 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2021.
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.